evidence boundary
supportsexperimental
An evidence atom is an inspectable support unit. It is not a finding by itself; it supports or challenges a finding through review.
frontiers / frontier
Evidence atom
back to sourcesevidence boundary
supportsAn evidence atom is an inspectable support unit. It is not a finding by itself; it supports or challenges a finding through review.
finding binding
boundDonanemab (anti-N3pG Aβ antibody) in Phase II TRAILBLAZER-ALZ reduced amyloid plaque load to near-zero in a majority of participants and slowed clinical decline on the iADRS by 32% versus placebo at 76 weeks in early symptomatic AD.
inspect finding →
source binding
source-boundvs_58f995dd73dc0057
inspect source →
review context
unverified2 reviewable changes and 0 evaluation records target this atom or its bound objects.
Evidence statement
Donanemab (anti-N3pG Aβ antibody) in Phase II TRAILBLAZER-ALZ reduced amyloid plaque load to near-zero in a majority of participants and slowed clinical decline on the iADRS by 32% versus placebo at 76 weeks in early symptomatic AD.
locator
source:Mark A. Mintun; Albert Lo; Cynthia Evans; Alette M. Wessels; Paul Ardayfio; Scott W. Andersen; Sergey Shcherbinin; JonDavid Sparks. New England Journal of Medicine 2021. doi:10.1056/NEJMoa2100708|section:curator_source
extraction method
manual_curation
support relation
supports
condition refs
vcnd_4a42444fa3367ee4
Caveats
No evidence-specific caveats are recorded.
events
vev_00bd89051d105094finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_4f1dbc7414c2957bfinding.reviewedTRAILBLAZER-ALZ Phase II (Mintun et al., NEJM 2021) was the foundational signal that donanemab clears amyloid plaques. Agent-drafted accept; eligible for human re-review.
agent:vela-curation-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_0c933959d5dd71abfinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_fe1facc0dc7a30c2finding.reviewTRAILBLAZER-ALZ Phase II (Mintun et al., NEJM 2021) was the foundational signal that donanemab clears amyloid plaques. Agent-drafted accept; eligible for human re-review.
applied · agent:vela-curation-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation rows are attached.